共 39 条
[1]
Van Gelder T(1995)A double-blind, placebo-controlled study of monoclonal anti-interleukin-2 receptor antibody (BT563) administration to prevent acute rejection after kidney transplantation Transplantation 60 248-52
[2]
Zietse R(1994)Treatment of steroid- resistant acute graft-vs-host disease after allogeneic marrow transplantation with anti-interleukin-2 receptor antibody (BT563) Transplant Proc 26 3114-6
[3]
Mulder AH(1993)Comparison of quadruple immunosuppression after liver transplantation with ATG or IL-2 receptor antibody Transplantation 55 1320-7
[4]
Hertenstein B(1996)Immunoprophylaxis with a monoclonal anti-IL-2 receptor antibody in liver transplant patients Transplantation 61 546-54
[5]
Stefanic M(1997)A prospective randomized trial comparing interleukin-2 receptor antibody versus antithymocyte globulin as part of a quadruple immunosuppressive induction therapy following orthotopic liver transplantation Transplantation 63 1772-81
[6]
Sandherr M(1997)Rescue therapy with interleukin-2 receptor antibody in high risk kidney transplant patients: a 3-year follow-up study Transplant Proc 29 320-2
[7]
Neuhaus P(1995)Pharmacodynamics of prophylactic antirejection therapy with an anti-interleukin-2 receptor monoclonal antibody (BT563) after heart and kidney transplantation Immunopharmacology 30 237-46
[8]
Bechstein WO(1992)Anti-interleukin-2 receptor monoclonal antibody (BT 563) in the treatment of severe acute GVHD refractory to systemic corticosteroid therapy Bone Marrow Transplant 10 451-5
[9]
Blumhardt G(1995)Intragraft monitoring of rejection after prophylactic treatment with monoclonal anti-interleukin-2 receptor antibody (BT563) in heart transplant recipients J Heart Lung Transplant 14 346-50
[10]
Nashan B(1998)Blockade of the interleukin (IL)-2/IL-2 receptor pathway with a monoclonal anti-IL-2 receptor antibody (BT563) does not prevent the development of acute heart allograft rejection in humans Transplantation 65 405-10